Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Apr;173(1):145-9.
doi: 10.1111/bjh.13937. Epub 2016 Feb 5.

Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia

Barbara Sandor  1 , Mickaël Marin  2   3   4 , Claudine Lapoumeroulie  2   3   4 , Miklos Rabaï  1 , Sophie D Lefevre  2   3   4   5 , Nathalie Lemonne  6 , Wassim El Nemer  2   3   4 , Anaïs Mozar  4   7 , Olivier Français  8 , Bruno Le Pioufle  8 , Philippe Connes  4   7   8   9   10 , Caroline Le Van Kim  2   3   4   5
Affiliations
Clinical Trial

Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia

Barbara Sandor et al. Br J Haematol. 2016 Apr.

Abstract

Vaso-occlusive crisis (VOC) is the main acute complication in sickle cell anaemia (SS) and several clinical trials are investigating different drugs to improve the clinical severity of SS patients. A phase III study is currently exploring the profit of Velopoloxamer in SS during VOCs. We analysed, in-vitro, the effect of poloxamer (P188) on red blood cell (RBC) properties by investigating haemorheology, mechanical and adhesion functions using ektacytometry, microfluidics and dynamic adhesion approaches, respectively. We show that poloxamer significantly reduces blood viscosity, RBC aggregation and adhesion to endothelial cells, supporting the beneficial use of this molecule in SS therapy.

Keywords: poloxamer; red blood cell; sickle cell anaemia.

PubMed Disclaimer

Publication types

LinkOut - more resources